Companion diagnostic tests in HIV medicine: The road to personalized medicine

AIDS Reader

Volumn 17, Issue 11, 2007, Pages 546-549

  Valenti, William M ^a,b  

^a Community Health Network ^*

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Diagnostic tests; HIV AIDS; Managed care; Pharmacogenomics; Reimbursement

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CITALOPRAM; ESCITALOPRAM; MARAVIROC; RISPERIDONE; SERTRALINE; TRASTUZUMAB; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VENLAFAXINE;

BREAST CANCER; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSTIC TEST; DNA SEQUENCE; DRUG EFFICACY; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MEDICAL RECORD; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; REIMBURSEMENT; REVIEW; TREATMENT OUTCOME; ARTICLE; DRUG DELIVERY SYSTEM; GENOME; HEALTH SERVICE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; HEALTH PROGRAM; HYPERSENSITIVITY; PERSONALIZED MEDICINE; PHENOTYPE; VIRAL TROPISM;

ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; GENOME, HUMAN; HIV INFECTIONS; HUMANS; PERSONAL HEALTH SERVICES;

EID: 39049113551     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Phillips KA, Veenstra DL, Owen E, et al. Potential role of pharmacogenomics in reducing drug reactions. JAMA. 2001;286:2270-2279.
2. Evans WE, Railing MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464-468.
3. EMEA Committee for Proprietary Medicinal Products (CPMP). Position Paper on Terminology in Pharmacogenetics. 3070/01. London: European Agency for the Evaluation of Medicinal Products; 2002.
4. Ross JS, Fletcher JA, Bloom KJ, et al. HER-2/neu testing in breast cancer. Am J Clin Pathol. 2003;120(suppl):S53-S71.
5. Jefferys DB, Bufton A, Gutman SI, Atkins D. Pharmacogenomic testing and regulation: the role of pharmacogenomics in pharmaceutical development and the regulation of pharmacogenetic test as in vitro diagnostics. Drug Inf J. January 2006. Available at: http://findarticles.com/p/articles/mi_qa3899/ is_200601/ai_ n17170684/pg_1. Accessed September 26, 2007.
6. Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions - Companion Guidance, September 10, 2007. Available at: www. fda.gov/cber/gdlns/pharmdtasubcomp.htm. Accessed September 26, 2007.
7. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B* 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-I reverse transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
8. Mallal S, Phillips E, Carosi G, et al. PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030). 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS101.
9. Saag M, Ive P, Heera P, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with zidovudine/lamivudine, for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS104.
10. Selzenrry (maraviroc) [package insert]. New York: Pfizer Labs; 2007. Available at: www.fda.gov/cder/foi/label/2007/022128lbl.pdf. Accessed September 26, 2007.
11. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359-1367.
12. Stawiski E, Whitcomb J, Coakley E, et al. Co-receptor tropism predictions based on V3 loop sequence in antiretroviral-experienced patients are specific but insensitive for the detection of CXCR4-using variants. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago. Abstract H-1028.
13. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47:75-85.
14. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15-27.
15. Blue Cross Blue Shield Association. Technology Evaluation Center. Technology Evaluation Center Criteria. Available at: www.bcbs.com/ betterknowledge/tec/tec-criteria.html. Accessed September 26, 2007.
16. Department of Health and Human Services. Secretary's Advisory Committee on Genetics, Health, and Society: Coverage and Reimbursement of Genetic Tests and Services. Available at: www4.od.nih.gov/oba/sacghs/reports/reports.html. Accessed September 28, 2007.